Corvus Pharmaceuticals, Inc.

CRVS Nasdaq SEC CIK 1626971
Follow Corvus Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$20.3M −100.3% vs same quarter last year
EPS, diluted −$0.22 −83.3% vs same quarter last year
Operating cash flow −$12.2M −27.7% vs same quarter last year
Operating income −$21.4M −102.1% vs same quarter last year
Net income by quarter
−$12.1M
−$8M
−$10.2M
−$12.3M
−$13.7M
−$18M
−$20.3M
Q4 24 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income12 fiscal years
−$80M−$60M−$40M−$20M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$15.3M
FY24−$62.3M
FY23−$27M
FY22−$41.3M
FY21−$43.2M
FY20−$6M
FY19−$46.7M
FY18−$46.9M
FY17−$55.7M
FY16−$36.4M
FY15−$31.3M
FY14-
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$33M
FY24-
FY23−$24M
FY22−$27.3M
FY21−$36.7M
FY20−$34.9M
FY19−$37.3M
FY18−$41.3M
FY17−$46.5M
FY16−$30.1M
FY15−$13.1M
FY14-